Poster: MDS-090: Phase II Study of the IDH2 Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
- 1 September 2021
- journal article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 21, S226
- https://doi.org/10.1016/s2152-2650(21)01427-0